Marshall Richard Henry Increases Stake in TLSI
Marshall Richard Henry, Chief Medical Officer, bought 120,000 shares of TLSI.
Key Points
- On June 29, 2026, Marshall Richard Henry, TLSI's Chief Medical Officer, purchased 120,000 shares.
- Shares of TLSI traded near $4.74 on Tuesday, reflecting recent insider activity.
- First Light Asset Management opened a new position in TLSI with 5,066,827 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Marshall Richard Henry, the Chief Medical Officer of TLSI, made a significant move by purchasing 120,000 shares of the company on June 29, 2026. This insider buying activity is notable as it shows confidence in the company's future.
Insider Buying and Selling at TriSalus Life Sciences, Inc.
On June 29, 2026, Marshall Richard Henry, TLSI's Chief Medical Officer, purchased 120,000 shares. Earlier that day, he also bought 60,000 shares. These transactions were not part of a pre-arranged trading plan. Meanwhile, on May 15, 2026, Richard Marshak, the Chief Commercial Officer, sold 543 shares at $2.67 each.
Other Institutional Activity in TLSI
First Light Asset Management opened a new position in TLSI, acquiring 5,066,827 shares valued at approximately $20.3 million. AWM Investment Company increased its holdings by 835,325 shares, reaching a total of 2,079,105 shares worth about $8.3 million, marking a 67.2% increase. Nantahala Capital Management held steady with 2,070,827 shares valued at $8.3 million. BlackRock trimmed its position by 34,789 shares, ending with 1,499,547 shares valued at around $6 million, a 2.3% decrease.
TriSalus Life Sciences, Inc. Stock Down 1.9%
Shares of TLSI traded near $4.74 on Tuesday. The company's stock has been drawing attention due to recent insider buying and institutional interest.
$TLSI stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 13, 2026, Lake Street maintained a 'buy' rating for TLSI with a price target of $8. Canaccord Genuity also maintained a 'buy' rating with a price target of $7, reiterated on March 9, 2026. The consensus among analysts is positive, with a 'buy' rating and an average price target reflecting optimism about TLSI's potential.
Bottom Line
The recent insider buying by Marshall Richard Henry suggests confidence in TLSI's prospects. Institutional interest further underscores this sentiment, as several funds have either opened new positions or increased their holdings. While these activities are positive indicators, it's important to remember that 13F filings and insider trades are backward-looking and may not reflect the current situation.
Get TriSalus Life Sciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TLSI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.